Attributes | Values |
---|
rdf:type
| |
Description
| - The ergot alkaloid derivative nicergoline became clinically available about 35 years ago in the 1970s. Nicergoline has a broad spectrum of action: (i) as an al-adrenoceptor antagonist, it induces vasodilation and increases arterial blood flow; (ii) it enhances cholinergic and catecholaminergic neurotransmitter function; (iii) it inhibits platelet aggregation; (iv) it promotes metabolic activity, resulting in increased utilization of oxygen and glucose; and (v) it has neurotrophic and antioxidant properties. Acting on several basic pathophysiological mechanisms, nicergoline has therapeutic potential in a number of disorders. This article provides an overview of the published clinical evidence relating to the efficacy and safety of nicergoline (30 mg twice daily) in the treatment of dementia (including Alzheimer's disease and vascular dementia) and vascular and balance disorders. For dementia of different aetiologies, the therapeutic benefit of nicergoline has been established, with up to 89% of p
- The ergot alkaloid derivative nicergoline became clinically available about 35 years ago in the 1970s. Nicergoline has a broad spectrum of action: (i) as an al-adrenoceptor antagonist, it induces vasodilation and increases arterial blood flow; (ii) it enhances cholinergic and catecholaminergic neurotransmitter function; (iii) it inhibits platelet aggregation; (iv) it promotes metabolic activity, resulting in increased utilization of oxygen and glucose; and (v) it has neurotrophic and antioxidant properties. Acting on several basic pathophysiological mechanisms, nicergoline has therapeutic potential in a number of disorders. This article provides an overview of the published clinical evidence relating to the efficacy and safety of nicergoline (30 mg twice daily) in the treatment of dementia (including Alzheimer's disease and vascular dementia) and vascular and balance disorders. For dementia of different aetiologies, the therapeutic benefit of nicergoline has been established, with up to 89% of p (en)
- Článek pojednává o nicergolinu, což námelový alkaloid používaný k léčbě různých typů demencí. Nicergolin má mnohočetné farmakologické účinky (antagonizace adrenergních alfa receptorů, zvýšení cholinergní a katecholaminergní transmise, inhibice agregace trombocytů). K dispozici je několik klinických studií u pacientů s vaskulární i Alzheimerovou demencí, které potvrzují jeho účinnost a bezpečnost. (cs)
|
Title
| - Therapeutic use of Nicergoline
- Terapeutické použití nicergolinu (cs)
- Therapeutic use of Nicergoline (en)
|
skos:prefLabel
| - Therapeutic use of Nicergoline
- Terapeutické použití nicergolinu (cs)
- Therapeutic use of Nicergoline (en)
|
skos:notation
| - RIV/00216208:11120/08:00000832!RIV09-MSM-11120___
|
http://linked.open...avai/riv/aktivita
| |
http://linked.open...avai/riv/aktivity
| |
http://linked.open...iv/cisloPeriodika
| |
http://linked.open...vai/riv/dodaniDat
| |
http://linked.open...aciTvurceVysledku
| |
http://linked.open.../riv/druhVysledku
| |
http://linked.open...iv/duvernostUdaju
| |
http://linked.open...titaPredkladatele
| |
http://linked.open...dnocenehoVysledku
| |
http://linked.open...ai/riv/idVysledku
| - RIV/00216208:11120/08:00000832
|
http://linked.open...riv/jazykVysledku
| |
http://linked.open.../riv/klicovaSlova
| - Amyloid Precursor Protein; Event-Related Potentials; Aged Rat-Brain; Double-Blind; Alzheimers-Disease; Vascular Dementia; Senile-Dementia; Vestibular Compensation; Cholinergic Deficits; Elderly-Patients (en)
|
http://linked.open.../riv/klicoveSlovo
| |
http://linked.open...odStatuVydavatele
| |
http://linked.open...ontrolniKodProRIV
| |
http://linked.open...i/riv/nazevZdroje
| - Clinical Drug Investigation
|
http://linked.open...in/vavai/riv/obor
| |
http://linked.open...ichTvurcuVysledku
| |
http://linked.open...cetTvurcuVysledku
| |
http://linked.open...UplatneniVysledku
| |
http://linked.open...v/svazekPeriodika
| |
http://linked.open...iv/tvurceVysledku
| - Doležal, Tomáš
- Winblad, B.
- Fioravanti, M.
- Logina, I.
- Milanov, I. G.
- Popescub, D. C.
- Solomon, A.
|
http://linked.open...ain/vavai/riv/wos
| |
issn
| |
number of pages
| |
http://localhost/t...ganizacniJednotka
| |